Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central nervous method, conolidine modulates alternate molecular targets. A Science Advances study observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://emilianodqtuv.blogsumer.com/36635249/not-known-factual-statements-about-conolidin-to-replace-traditional-painkillers